Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds

Iatrogenic sexual dysfunction (SD) caused by antihypertensive (AH) compounds, provoking sexual desire, orgasm or arousal dysfunction, is a common clinical adverse event. Unfortunately, it is often underestimated and underreported by clinicians and prescribers in clinical practice, deteriorating the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bárbara Buch-Vicente, José Mª. Acosta, José-Angel Martín-Oterino, Nieves Prieto, María Elena Sánchez-Sánchez, Purificación Galindo-Villardón, Angel L. Montejo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	sexual dysfunction antihypertensive treatment hypertension PRSexDQ-SALSEX blood pressure Medicine R
Acceso en línea:	https://doaj.org/article/ab0a393db3ca4bbabcf5f683f4a96759
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab0a393db3ca4bbabcf5f683f4a96759
record_format	dspace
spelling	oai:doaj.org-article:ab0a393db3ca4bbabcf5f683f4a967592021-11-25T18:00:32ZFrequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds10.3390/jcm102252142077-0383https://doaj.org/article/ab0a393db3ca4bbabcf5f683f4a967592021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5214https://doaj.org/toc/2077-0383Iatrogenic sexual dysfunction (SD) caused by antihypertensive (AH) compounds, provoking sexual desire, orgasm or arousal dysfunction, is a common clinical adverse event. Unfortunately, it is often underestimated and underreported by clinicians and prescribers in clinical practice, deteriorating the adherence and patient quality of life. The objective of this study was to investigate the frequency of SD in patients treated with different antihypertensive compounds; a real-life naturalistic and cross-sectional study in patients receiving AH treatment was carried out. Method: A total of 256 patients were included in the study (188 males and 68 females who met the inclusion and exclusion criteria). The validated Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) was transversally applied once at least every two months following the onset of the treatment in order to measure possible AH-related SD. Although the spontaneous reporting of SD was very low (6.81% females/24.8% males), 66.40% of the patients reported impaired sexual function through the SALSEX questionnaire after the treatment onset, as follows: decreased desire (55.8% females/54.2% males), delayed orgasm (42.6%/45.7%), anorgasmia (42.6%/43.6%) and arousal difficulties (53%/59.6%). The average frequency of moderate to severe iatrogenic SD was 66.4% with AH in monotherapy as follows: angiotensin II receptor antagonists (ARBs), 29.8%; calcium antagonists, 40%; diuretics, 42.9%; beta blockers, 43.8%; and angiotensin-converting enzyme (ACE) inhibitors, 77.8%. Combined treatments showed a higher percentage of main SD (70.3%): diuretic + ACE inhibitor, 42.3%; ARB + calcium antagonist, 55.6%; diuretic + calcium antagonist, 68.8%; and diuretic + ARB, 74.2%. The greatest risk factors associated with SD were poor general health, age over 60 with a comorbid coronary or musculoskeletal disease, mood disorder and diuretic +ARB combined therapy. Conclusion: SD is common in patients treated with antihypertensive drugs, and it is still underreported. The most harmful treatment deteriorating sexual function was the combination of diuretic +ARB, while the least harmful was monotherapy with ARBs. More research is needed on the clinical management of this problem to preserve the quality of life of patients and their partners.Bárbara Buch-VicenteJosé Mª. AcostaJosé-Angel Martín-OterinoNieves PrietoMaría Elena Sánchez-SánchezPurificación Galindo-VillardónAngel L. MontejoMDPI AGarticlesexual dysfunctionantihypertensive treatmenthypertensionPRSexDQ-SALSEXblood pressureMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5214, p 5214 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sexual dysfunction antihypertensive treatment hypertension PRSexDQ-SALSEX blood pressure Medicine R
spellingShingle	sexual dysfunction antihypertensive treatment hypertension PRSexDQ-SALSEX blood pressure Medicine R Bárbara Buch-Vicente José Mª. Acosta José-Angel Martín-Oterino Nieves Prieto María Elena Sánchez-Sánchez Purificación Galindo-Villardón Angel L. Montejo Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds
description	Iatrogenic sexual dysfunction (SD) caused by antihypertensive (AH) compounds, provoking sexual desire, orgasm or arousal dysfunction, is a common clinical adverse event. Unfortunately, it is often underestimated and underreported by clinicians and prescribers in clinical practice, deteriorating the adherence and patient quality of life. The objective of this study was to investigate the frequency of SD in patients treated with different antihypertensive compounds; a real-life naturalistic and cross-sectional study in patients receiving AH treatment was carried out. Method: A total of 256 patients were included in the study (188 males and 68 females who met the inclusion and exclusion criteria). The validated Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) was transversally applied once at least every two months following the onset of the treatment in order to measure possible AH-related SD. Although the spontaneous reporting of SD was very low (6.81% females/24.8% males), 66.40% of the patients reported impaired sexual function through the SALSEX questionnaire after the treatment onset, as follows: decreased desire (55.8% females/54.2% males), delayed orgasm (42.6%/45.7%), anorgasmia (42.6%/43.6%) and arousal difficulties (53%/59.6%). The average frequency of moderate to severe iatrogenic SD was 66.4% with AH in monotherapy as follows: angiotensin II receptor antagonists (ARBs), 29.8%; calcium antagonists, 40%; diuretics, 42.9%; beta blockers, 43.8%; and angiotensin-converting enzyme (ACE) inhibitors, 77.8%. Combined treatments showed a higher percentage of main SD (70.3%): diuretic + ACE inhibitor, 42.3%; ARB + calcium antagonist, 55.6%; diuretic + calcium antagonist, 68.8%; and diuretic + ARB, 74.2%. The greatest risk factors associated with SD were poor general health, age over 60 with a comorbid coronary or musculoskeletal disease, mood disorder and diuretic +ARB combined therapy. Conclusion: SD is common in patients treated with antihypertensive drugs, and it is still underreported. The most harmful treatment deteriorating sexual function was the combination of diuretic +ARB, while the least harmful was monotherapy with ARBs. More research is needed on the clinical management of this problem to preserve the quality of life of patients and their partners.
format	article
author	Bárbara Buch-Vicente José Mª. Acosta José-Angel Martín-Oterino Nieves Prieto María Elena Sánchez-Sánchez Purificación Galindo-Villardón Angel L. Montejo
author_facet	Bárbara Buch-Vicente José Mª. Acosta José-Angel Martín-Oterino Nieves Prieto María Elena Sánchez-Sánchez Purificación Galindo-Villardón Angel L. Montejo
author_sort	Bárbara Buch-Vicente
title	Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds
title_short	Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds
title_full	Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds
title_fullStr	Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds
title_full_unstemmed	Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds
title_sort	frequency of iatrogenic sexual dysfunction associated with antihypertensive compounds
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ab0a393db3ca4bbabcf5f683f4a96759
work_keys_str_mv	AT barbarabuchvicente frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds AT josemaacosta frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds AT joseangelmartinoterino frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds AT nievesprieto frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds AT mariaelenasanchezsanchez frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds AT purificaciongalindovillardon frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds AT angellmontejo frequencyofiatrogenicsexualdysfunctionassociatedwithantihypertensivecompounds
_version_	1718411765202550784

Frequency of Iatrogenic Sexual Dysfunction Associated with Antihypertensive Compounds

Ejemplares similares